S&P 500
7,596.68
+16.61
+0.22%
Dow
52,251.31
+481.00
+0.93%
Nasdaq
25,453.56
+16.56
+0.07%
NYSE Composite
24,467.58
+174.49
+0.72%
Russell 2000
2,825.84
+13.99
+0.50%
VIX
19.70
+0.28
+1.44%
MLYS · Mineralys Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$15.90
-2.27
(-12.49%)
● Market open
DAY'S RANGE
$15.90
$15.72
$18.29
52-WEEK RANGE
$15.90
$18.11
$47.65
What's happening
- MLYS is down 12.49% today, trading at $15.90. — Live quote
- It's trading within 3% of its 52-week low ($18.11). (Finnhub fundamentals)
- Volume today (128,354) is well below its 3-month average of 1,209,770. (Finnhub fundamentals)
- Reports earnings on 2026-11-04 (after market close), 2 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-2.85 actual vs. $-0.55 estimated (-422.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 9
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-11-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MLYS
-49.90%
vs S&P 500
-60.73%
1-YEAR RETURN
MLYS
-55.79%
vs S&P 500
-66.95%
6-MONTH RETURN
MLYS
-29.78%
3-MONTH RETURN
MLYS
-28.76%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-2.85
Est. $-0.55
MISS -422.3%
2026-04-26 (Q1 2026)
$-0.47
Est. $-0.47
BEAT +0.1%
2026-01-26 (Q4 2025)
$-0.40
Est. $-0.54
BEAT +26.4%
2025-10-26 (Q3 2025)
$-0.52
Est. $-0.63
BEAT +17.8%
Valuation Measures & Ratios
Enterprise Value4$1.57B
Forward P/E5—
PEG Ratio6-0.26
Price / Sales (TTM1)—
Price / Book74.32
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-57.97%
Return on Assets (ROA9)-54.15%
Avg Volume (3M)1,209,770
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.28B | $2.27B | $2.70B | $888.4M | $849.6M |
| P/E | -6.34 | -14.01 | -15.09 | -4.86 | -4.97 |
| Price/Book | 4.15 | 3.55 | 4.68 | 2.83 | 2.49 |
| EV/EBITDA | -5.66 | -12.13 | -12.89 | — | — |
| ROE | -65.46% | -25.35% | -31.01% | -58.31% | -50.09% |
| ROA | -54.00% | -24.78% | -29.80% | -54.46% | -48.20% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short7,438,452
Change from Prior Settlement-4.70%
% of Float—
Days to Cover (Short Ratio)5.33
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-10-15. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-29; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -55.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MLYS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$246.0M | -$45.3M | -$41.1M | -$46.7M | -$44.4M | -$60.1M | -$45.2M | -$35.4M |
| Net income | -$241.1M | -$39.3M | -$36.9M | -$43.3M | -$42.2M | -$56.3M | -$41.0M | -$31.5M |
| EPS (diluted) | $-2.85 | $-0.47 | $-0.52 | $-0.66 | $-0.79 | $-1.13 | $-0.83 | $-0.70 |
| EPS (basic) | $-2.85 | $-0.47 | $-0.52 | $-0.66 | $-0.79 | $-1.13 | $-0.83 | $-0.70 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $667.9M | $652.9M | $661.8M | $599.9M | $335.7M | $354.9M | $205.9M | $268.3M |
| Total liabilities | $116.9M | — | $15.1M | — | — | — | — | — |
| Stockholders' equity | $550.9M | $638.1M | $646.7M | $576.4M | $313.6M | $341.6M | $191.3M | $236.9M |
| Total current assets | $665.8M | $652.5M | $661.4M | $599.8M | $335.3M | $354.5M | $205.4M | $267.7M |
| Total current liabilities | $19.3M | $14.7M | $15.1M | $23.5M | $22.2M | $13.4M | $14.6M | $31.3M |
| Cash & equivalents | $138.3M | $112.8M | $172.9M | $217.6M | $101.8M | $165.0M | $114.1M | $97.3M |
| Marketable securities (non-current) | — | — | — | — | — | — | $0 | — |
| Property, plant & equipment | $27.0K | $32.0K | $38.0K | $7.0K | $22.0K | $38.0K | $53.0K | $69.0K |
| Other non-current assets | $2.0M | $360.0K | $382.0K | $144.0K | $433.0K | $397.0K | $499.0K | $452.0K |
| Accounts payable | $1.1M | $1.1M | $2.0M | $1.1M | $3.2M | $373.0K | $479.0K | $3.1M |
| Accrued liabilities | $18.3M | $13.6M | $13.1M | $22.4M | $19.0M | $13.0M | $14.2M | $28.2M |
| Long-term debt | $100.0K | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $9.0K | $8.0K | $8.0K | $8.0K | $6.0K | $6.0K | $5.0K | $5.0K |
| Retained earnings | -$737.6M | -$496.5M | -$457.2M | -$424.9M | -$388.0M | -$344.7M | -$302.5M | -$253.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.6M | -$39.5M | -$37.9M | -$28.9M | -$30.2M | -$45.5M | -$66.8M | -$50.2M |
| Investing cash flow | -$185.2M | -$44.9M | -$103.5M | -$150.5M | -$42.9M | -$92.9M | $83.6M | $79.6M |
| Financing cash flow | $243.3M | $24.3M | $96.7M | $295.2M | $9.8M | $189.3M | $90.0K | -$1.0K |
| Depreciation & amortization | $5.0K | $6.0K | $13.0K | $15.0K | $16.0K | $15.0K | $15.0K | $11.0K |
| Share-based compensation | $7.4M | $6.5M | $5.3M | $5.8M | $4.6M | $3.6M | $3.1M | $3.1M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating income | -$170.6M | -$192.4M | -$84.7M | -$31.5M |
| Net income | -$154.7M | -$177.8M | -$71.9M | -$29.8M |
| EPS (diluted) | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
| EPS (basic) | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $661.8M | $205.9M | $251.6M | $114.4M | — |
| Stockholders' equity | $646.7M | $191.3M | $241.2M | -$52.3M | -$22.9M |
| Total current assets | $661.4M | $205.4M | $249.1M | $112.8M | — |
| Total current liabilities | $15.1M | $14.6M | $10.5M | $8.1M | — |
| Cash & equivalents | $172.9M | $114.1M | $49.3M | $87.7M | — |
| Marketable securities (non-current) | — | $0 | $2.5M | — | — |
| Property, plant & equipment | $38.0K | $53.0K | $0 | — | — |
| Other non-current assets | $382.0K | $499.0K | $51.0K | $1.6M | — |
| Accounts payable | $2.0M | $479.0K | $601.0K | $1.9M | — |
| Accrued liabilities | $13.1M | $14.2M | $9.9M | $6.2M | — |
| Common stock & paid-in capital | $8.0K | $5.0K | $4.0K | $1.0K | — |
| Retained earnings | -$457.2M | -$302.5M | -$124.7M | -$52.8M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating cash flow | -$142.4M | -$166.3M | -$81.2M | -$29.2M |
| Investing cash flow | -$389.8M | $115.0M | -$160.5M | -$21.8M |
| Financing cash flow | $591.0M | $116.1M | $203.2M | $128.0M |
| Depreciation & amortization | $59.0K | $43.0K | $0 | — |
| Share-based compensation | $19.3M | $11.3M | $5.1M | $455.0K |
| Deferred income taxes | $0 | $0 | $0 | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MLYS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers90.0%
Shares Outstanding84,727,282
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 7,903,838 | $213.2M | 9.33% | +0.0% | 2026-08-05 |
| RA CAPITAL MANAGEMENT, L.P. | 7,692,750 | $207.6M | 9.08% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 5,887,038 | $158.8M | 6.95% | +31.4% | 2026-08-07 |
| Samsara BioCapital, LLC | 5,871,018 | $158.4M | 6.93% | +0.0% | 2026-08-14 |
| FMR LLC | 4,511,689 | $121.7M | 5.32% | -7.2% | 2026-08-13 |
| State Street Corp | 4,141,636 | $111.7M | 4.89% | +41.1% | 2026-08-07 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3,958,000 | $106.8M | 4.67% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,756,770 | $74.4M | 3.25% | +12.3% | 2026-06-30 |
| Laurion Capital Management LP | 2,506,152 | $67.6M | 2.96% | +12.3% | 2026-08-07 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2,262,476 | $61.0K | 2.67% | +68.4% | 2026-08-14 |
| ORBIMED ADVISORS LLC | 2,110,300 | $56.9M | 2.49% | +2.8% | 2026-08-14 |
| Capital World Investors | 1,997,607 | $53.9M | 2.36% | +401.7% | 2026-08-07 |
| ARMISTICE CAPITAL, LLC | 1,736,000 | $46.8M | 2.05% | +47.6% | 2026-08-14 |
| Troluce Capital Advisors LLC | 1,728,753 | $46.6M | 2.04% | +163.9% | 2026-08-14 |
| Franklin Resources Inc | 1,635,520 | $44.1M | 1.93% | -8.4% | 2026-08-04 |
| Andera Partners | 1,591,917 | $42.9M | 1.88% | +0.0% | 2026-07-22 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,584,326 | $42.8M | 1.87% | +21.8% | 2026-08-12 |
| SR ONE CAPITAL MANAGEMENT, LP | 1,563,966 | $42.2M | 1.85% | +0.0% | 2026-08-12 |
| Bank Of America Corp /De/ | 1,505,547 | $40.6M | 1.78% | +36.8% | 2026-08-14 |
| SPHERA FUNDS MANAGEMENT LTD. | 1,469,971 | $39.7M | 1.73% | +9.7% | 2026-08-14 |
| Goldman Sachs Group Inc | 1,458,676 | $39.4M | 1.72% | +85.8% | 2026-08-14 |
| Pictet Asset Management Holding SA | 1,430,649 | $38.6M | 1.69% | +38.3% | 2026-07-30 |
| Polar Capital Holdings Plc | 1,420,854 | $38.3M | 1.68% | -5.3% | 2026-08-14 |
| MILLENNIUM MANAGEMENT LLC | 1,221,758 | $33.0M | 1.44% | +132.6% | 2026-08-14 |
| Ghisallo Capital Management LLC | 1,125,000 | $30.4M | 1.33% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-09 to 2026-10-19
Recent transactions
- Insiders have net sold 468,606 shares over the last 182 days, across 0 purchases and 24 sales.
- Most recent: Peterson Kristine (Director) — Grant / award of 12,400 shares on 2026-10-19.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)468,606 sh(24 txns)
Net Shares-468,606
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Peterson Kristine | Director | Grant / award | 2026-10-19 | 12,400 |
| COATS LONNEL | Director | Grant / award | 2026-10-19 | 12,400 |
| Congleton Jon | Chief Executive Officer | Open market sale | 2026-09-30 | 75,000 |
| Slingsby Brian Taylor | Director | Open market sale | 2026-09-22 | 104,320 |
| Warren Eric | Chief Commercial Officer | Option exercise | 2026-09-21 | 7,438 |
| Karydas Daphne | Director | Option exercise | 2026-09-15 | 3,000 |
| Ferguson James J. III | Chief Medical Officer | Grant / award | 2026-08-10 | 102,400 |
| Rodman David Malcom | Chief Medical Officer | Option exercise | 2026-08-10 | 2,170 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-19 | Peterson Kristine | Director | Grant / award | 12,400 | $0.00 |
| 2026-10-19 | COATS LONNEL | Director | Grant / award | 12,400 | $0.00 |
| 2026-09-30 | Congleton Jon | Chief Executive Officer | Open market sale | 75,000 | $25.46 |
| 2026-09-22 | Slingsby Brian Taylor | Director | Open market sale | 104,320 | $28.81 |
| 2026-09-21 | Warren Eric | Chief Commercial Officer | Option exercise | 7,438 | $13.24 |
| 2026-09-21 | Warren Eric | Chief Commercial Officer | Open market sale | 7,438 | $28.12 |
| 2026-09-15 | Karydas Daphne | Director | Option exercise | 3,000 | $12.02 |
| 2026-09-15 | Karydas Daphne | Director | Open market sale | 3,000 | $28.58 |
| 2026-08-21 | Warren Eric | Chief Commercial Officer | Option exercise | 7,437 | $13.24 |
| 2026-08-21 | Warren Eric | Chief Commercial Officer | Open market sale | 7,437 | $25.98 |
| 2026-08-10 | Ferguson James J. III | Chief Medical Officer | Grant / award | 102,400 | $0.00 |
| 2026-08-10 | Rodman David Malcom | Chief Medical Officer | Option exercise | 2,170 | $16.00 |
| 2026-08-10 | Rodman David Malcom | Chief Medical Officer | Open market sale | 2,170 | $27.09 |
| 2026-07-21 | Warren Eric | Chief Commercial Officer | Option exercise | 7,438 | $13.24 |
| 2026-07-21 | Warren Eric | Chief Commercial Officer | Open market sale | 7,438 | $26.87 |
| 2026-07-17 | Rodman David Malcom | Chief Medical Officer | Option exercise | 416 | $15.44 |
| 2026-07-17 | Rodman David Malcom | Chief Medical Officer | Open market sale | 416 | $26.53 |
| 2026-07-15 | Rodman David Malcom | Chief Medical Officer | Open market sale | 6,349 | $26.61 |
| 2026-07-13 | Congleton Jon | Chief Executive Officer | Open market sale | 10,700 | $27.24 |
| 2026-07-13 | Rodman David Malcom | Chief Medical Officer | Option exercise | 3,542 | $10.20 |
| 2026-07-13 | Rodman David Malcom | Chief Medical Officer | Option exercise | 4,167 | $14.25 |
| 2026-07-13 | Rodman David Malcom | Chief Medical Officer | Option exercise | 6,349 | $1.08 |
| 2026-07-13 | Rodman David Malcom | Chief Medical Officer | Open market sale | 14,058 | $27.58 |
| 2026-07-09 | Rodman David Malcom | Chief Medical Officer | Option exercise | 2,171 | $16.00 |
| 2026-07-09 | Rodman David Malcom | Chief Medical Officer | Open market sale | 2,171 | $30.30 |
| 2026-06-30 | Congleton Jon | Chief Executive Officer | Open market sale | 58,000 | $25.94 |
| 2026-06-30 | Congleton Jon | Chief Executive Officer | Open market sale | 17,000 | $26.82 |
| 2026-06-26 | Warren Eric | Chief Commercial Officer | Option exercise | 104,124 | $13.24 |
| 2026-06-26 | Warren Eric | Chief Commercial Officer | Open market sale | 104,124 | $25.90 |
| 2026-06-17 | Rodman David Malcom | Chief Medical Officer | Option exercise | 4,167 | $14.25 |
| 2026-06-17 | Rodman David Malcom | Chief Medical Officer | Option exercise | 417 | $15.44 |
| 2026-06-17 | Rodman David Malcom | Chief Medical Officer | Open market sale | 4,584 | $25.00 |
| 2026-06-17 | Karydas Daphne | Director | Option exercise | 3,000 | $12.02 |
| 2026-06-17 | Karydas Daphne | Director | Open market sale | 3,000 | $25.00 |
| 2026-06-15 | Rodman David Malcom | Chief Medical Officer | Option exercise | 3,542 | $10.20 |
| 2026-06-15 | Rodman David Malcom | Chief Medical Officer | Open market sale | 9,890 | $23.81 |
| 2026-06-12 | Rodman David Malcom | Chief Medical Officer | Option exercise | 6,349 | $1.08 |
| 2026-06-12 | Rodman David Malcom | Chief Medical Officer | Open market sale | 6,349 | $23.93 |
| 2026-06-10 | Rodman David Malcom | Chief Medical Officer | Option exercise | 2,170 | $16.00 |
| 2026-06-10 | Rodman David Malcom | Chief Medical Officer | Open market sale | 2,170 | $25.00 |
| 2026-05-18 | Rodman David Malcom | Chief Medical Officer | Option exercise | 417 | $15.44 |
| 2026-05-18 | Rodman David Malcom | Chief Medical Officer | Open market sale | 417 | $27.55 |
| 2026-05-13 | Rodman David Malcom | Chief Medical Officer | Option exercise | 3,541 | $10.20 |
| 2026-05-13 | Rodman David Malcom | Chief Medical Officer | Option exercise | 4,166 | $14.25 |
| 2026-05-13 | Rodman David Malcom | Chief Medical Officer | Open market sale | 14,056 | $28.58 |
| 2026-05-12 | Rodman David Malcom | Chief Medical Officer | Option exercise | 6,348 | $1.08 |
| 2026-05-12 | Rodman David Malcom | Chief Medical Officer | Open market sale | 6,348 | $29.36 |
| 2026-05-11 | Rodman David Malcom | Chief Medical Officer | Option exercise | 2,171 | $16.00 |
| 2026-05-11 | Rodman David Malcom | Chief Medical Officer | Open market sale | 2,171 | $29.71 |
| 2026-04-17 | Rodman David Malcom | Chief Medical Officer | Option exercise | 416 | $15.44 |
| 2026-04-17 | Rodman David Malcom | Chief Medical Officer | Open market sale | 416 | $31.33 |
| 2026-04-15 | Rodman David Malcom | Chief Medical Officer | Open market sale | 6,348 | $27.66 |
| 2026-04-13 | Rodman David Malcom | Chief Medical Officer | Option exercise | 6,349 | $1.08 |
| 2026-04-13 | Rodman David Malcom | Chief Medical Officer | Option exercise | 3,542 | $10.20 |
| 2026-04-13 | Rodman David Malcom | Chief Medical Officer | Option exercise | 4,167 | $14.25 |
| 2026-04-13 | Rodman David Malcom | Chief Medical Officer | Open market sale | 14,058 | $26.54 |
| 2026-04-13 | Congleton Jon | Chief Executive Officer | Open market sale | 15,730 | $26.83 |
| 2026-04-09 | Rodman David Malcom | Chief Medical Officer | Option exercise | 2,170 | $16.00 |
| 2026-04-09 | Rodman David Malcom | Chief Medical Officer | Open market sale | 2,170 | $27.38 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-11-02 15:29 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-29 | 8-K | 2026-10-27 | View on SEC.gov → |
| 2026-10-20 | 4 | 2026-10-19 | View on SEC.gov → |
| 2026-10-20 | 4 | 2026-10-19 | View on SEC.gov → |
| 2026-10-19 | 8-K | 2026-10-16 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-24 | 4 | 2026-09-22 | View on SEC.gov → |
| 2026-09-22 | 4 | 2026-09-21 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about MLYS (Mineralys Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Behavioral Patterns of MLYS and Institutional Flows
Stock Traders Daily · 2026-11-02 -
Mineralys Therapeutics, Inc. (MLYS) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-11-01 -
Kidney Trial Results Could Change The Case For Mineralys Therapeutics Stock
Yahoo · 2026-11-01 -
Mineralys Therapeutics stock hits 52-week low at $20.03 By Investing.com
Investing.com South Africa · 2026-10-30 -
Mineralys Therapeutics will report financial results after stock ends session up 1.1%
Traders Union · 2026-10-28 -
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
Yahoo · 2026-10-28 -
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Yahoo · 2026-10-28 -
Mineralys Therapeutics Announces Phase 2 Explore-CKD Trial Met Its Primary Endpoint; Publishes Full Results In The Journal 'Kidney International'
Benzinga · 2026-10-28
No headlines in this category right now — try “All”.